While knockout of STAT3 inhibited the CML cells from developing drug-persistence, inhibition of STAT3 using a small molecule inhibitor sensitized the persistent CML cells to TKI treatment. Here, STAT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.